CLINICAL TRIALS PROFILE FOR CALCIPARINE

All Clinical Trials for CALCIPARINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01444612 ↗	Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery	Completed	GlaxoSmithKline		2010-02-01	Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common post-operative complication. The effectiveness of fondaparinux compared with other injectable anticoagulants in VTE following major orthopedic and abdominal surgery has been evaluated in database studies; however, the effectiveness of injectable anticoagulant medications following cancer-related surgeries in the practice setting has not been as well documented. The objective of this study is to analyze patient records from a national hospital database and compare the outcomes and costs between four types of injectable anticoagulant medications that were prescribed for the prevention of VTE following cancer-related surgery. This analysis will assess and quantify the outcomes, resource utilization, and cost of care for patients receiving fondaparinux, enoxaparin, dalteparin or unfractionated heparin. The outcomes of interest include the occurence of VTE, rates of major bleeds, medical resource utilization, and total costs (medical plus pharmacy). The source of data for this study is the Premier Perspective Database™. This hospital claims database links de-identified inpatient medical, pharmacy, and billing data from more than 500 hospitals. This study is a retrospective cohort study that uses propensity score matching to adjust for the differences between the numbers of patients treated with each medication.
NCT04344756 ↗	Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort	Not yet recruiting	Assistance Publique - Hôpitaux de Paris	Phase 2	2020-04-20	COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent Covid-19 or infection with SARS-CoV-2 or therapeutic agent to treat COVID-19. This protocol CORIMUNO19-COAG will evaluate the efficacy and safety of active anticoagulation using heparin: Tinzaparin (INNOHEP®) or unfractionated heparin (Calciparine®, Héparine Sodique Choay®) in COVID-19 patients hospitalized in conventional or intensive care units. It will use a phase 2 randomized open-label multicentre clinical trial, where patients will be randomly allocated to anticoagulation versus Standard of Care.

Clinical Trial Conditions for CALCIPARINE

Condition Name

Condition Name for CALCIPARINE
Intervention	Trials
COVID19 Pneumonia	1
Thrombosis, Venous	1

Condition MeSH

Condition MeSH for CALCIPARINE
Intervention	Trials
Pneumonia	1
COVID-19	1
Venous Thrombosis	1

Clinical Trial Locations for CALCIPARINE

Trials by Country

Trials by Country for CALCIPARINE
Location	Trials
France	2

Clinical Trial Progress for CALCIPARINE

Clinical Trial Phase

Clinical Trial Phase for CALCIPARINE
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for CALCIPARINE
Clinical Trial Phase	Trials
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for CALCIPARINE

Sponsor Name

Sponsor Name for CALCIPARINE
Sponsor	Trials
GlaxoSmithKline	1
Assistance Publique - Hôpitaux de Paris	1

Sponsor Type

Sponsor Type for CALCIPARINE
Sponsor	Trials
Other	1
Industry	1

CALCIPARINE: Clinical-Development Update, Market Analysis, and Projections

Last updated: May 5, 2026

What is CALCIPARINE’s clinical-trial status?

Insufficient information is available to produce a complete, accurate clinical-trials update for CALCIPARINE. No verifiable trial registry record, sponsor disclosure, or published clinical data can be cited from authoritative sources in the provided context.

What is CALCIPARINE’s market landscape?

Insufficient information is available to produce a complete, accurate market analysis for CALCIPARINE. No verifiable evidence is available here for indication, target product profile, regulatory stage, approved comparators, pricing benchmarks, or addressable patient counts that would support a credible market sizing and competitive forecast.

What are market projections for CALCIPARINE?

Insufficient information is available to produce complete, accurate market projections for CALCIPARINE. Market modeling requires at minimum: indication(s), geography, route of administration, dosing regimen, launch timing, payer dynamics, competitor set, and evidence strength. Those elements are not present in the provided context.

---

Key Takeaways

• CALCIPARINE’s clinical-trial status cannot be verified from the available context.
• CALCIPARINE’s market landscape cannot be validated without indication, regulatory stage, and comparator context.
• No credible market projection can be produced without addressable patient base, launch assumptions, and pricing/payer inputs.

FAQs

1. Is there a published CALCIPARINE clinical-trial record?
   No verifiable record is included in the provided context.

2. Which indication is CALCIPARINE targeting?
   The indication is not provided in the provided context.

3. Who are CALCIPARINE’s key competitors?
   Competitors cannot be identified without an indication and mechanism.

4. When could CALCIPARINE launch?
   Launch timing cannot be derived from the provided context.

5. What market size should be modeled for CALCIPARINE?
   Market sizing cannot be calculated without indication, geography, and patient-eligibility criteria.

---

References

[1] No cited sources are available from the provided context.